Aurinia Pharmaceuticals Inc.
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
AUPH | NDAQ
Overview
Corporate Details
- ISIN(s):
- CA05156V1022
- LEI:
- Country:
- United States of America
- Address:
- #140, 14315 - 118 AVENUE, EDMONTON
- Website:
- https://www.auriniapharma.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and delivering innovative therapies to treat autoimmune diseases with high unmet medical needs. The company's primary area of research and development is in the field of immunology and nephrology. Its core efforts are centered on the development of voclosporin, an investigational drug aimed at treating serious conditions such as lupus nephritis (LN), a severe inflammation of the kidneys, and other proteinuric diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aurinia Pharmaceuticals Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aurinia Pharmaceuticals Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aurinia Pharmaceuticals Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
